Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · IEX Real-Time Price · USD

84.79

-0.06 (-0.07%)

At close: Jul 2, 2024, 4:00 PM

83.14

-1.65 (-1.95%)

After-hours: Jul 2, 2024, 4:03 PM EDT

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1994
Net Income	52.15	-33.36	57.14	-2.99	629.3	Upgrade
Depreciation & Amortization	37.38	56.89	55.79	29.58	43.73	Upgrade
Share-Based Compensation	25.74	60.29	38.78	30.73	24.52	Upgrade
Other Operating Activities	-65.7	54.04	-72.91	-2.73	-726.88	Upgrade
Operating Cash Flow	49.58	137.85	78.8	54.59	-29.34	Upgrade
Operating Cash Flow Growth	-64.04%	74.94%	44.36%	-	-	Upgrade
Capital Expenditures	-53.43	-17.83	-8.27	-3.1	-2.55	Upgrade
Acquisitions	-25.65	-0.75	0	-382.82	-11.84	Upgrade
Change in Investments	67.4	183.17	40.01	615.67	-326.82	Upgrade
Other Investing Activities	-	-0.96	-1.22	1.9	808.13	Upgrade
Investing Cash Flow	-11.68	163.62	30.52	231.65	466.92	Upgrade
Share Issuance / Repurchase	22.45	3.23	33.76	-74.98	-450.05	Upgrade
Debt Issued / Paid	-77.85	-260.8	-146.01	-231.76	-27.32	Upgrade
Other Financing Activities	-4.55	-16.88	-6.02	-3.81	-7.8	Upgrade
Financing Cash Flow	-59.95	-274.45	-118.27	-310.55	-485.17	Upgrade
Exchange Rate Effect	-	0	0	0	0.08	Upgrade
Net Cash Flow	0	0	0	-24.31	-47.59	Upgrade
Free Cash Flow	-3.85	120.02	70.53	51.49	-31.89	Upgrade
Free Cash Flow Growth	-	70.16%	36.99%	-	-	Upgrade
Free Cash Flow Margin	-2.93%	61.16%	29.20%	31.48%	-26.51%	Upgrade
Free Cash Flow Per Share	-0.22	7.12	4.24	3.18	-1.68	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).